Heart disease, clinical proteomics and mass spectrometry

Brian A. Stanley, Rebekah L. Gundry, Robert J. Cotter, Jennifer E. Van Eyk

Research output: Contribution to journalReview article

62 Citations (Scopus)

Abstract

Heart disease is the leading cause of mortality and morbidity in the world. As such, biomarkers are needed for the diagnosis, prognosis, therapeutic monitoring and risk stratification of acute injury (acute myocardial infarction (AMI)) and chronic disease (heart failure). The procedure for biomarker development involves the discovery, validation, and translation into clinical practice of a panel of candidate proteins to monitor risk of heart disease. Two types of biomarkers are possible; heart-specific and cardiovascular pulmonary system monitoring markers. Here we review the use of MS in the process of cardiac biomarker discovery and validation by proteomic analysis of cardiac myocytes/tissue or serum/plasma. An example of the use of MS in biomarker discovery is given in which the albumin binding protein sub-proteome was examined using MALDI-TOF MS/MS. Additionally, an example of MS in protein validation is given using affinity surface enhanced laser desorption ionization (SELDI) to monitor the disease-induced post-translational modification and the ternary status of myoctye-originating protein, cardiac troponin I in serum.

Original languageEnglish (US)
Pages (from-to)167-178
Number of pages12
JournalDisease Markers
Volume20
Issue number3
DOIs
StatePublished - Jan 1 2004

Fingerprint

Biomarkers
Proteomics
Mass spectrometry
Heart Diseases
Mass Spectrometry
Proteins
Troponin I
Monitoring
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Proteome
Post Translational Protein Processing
Cardiovascular System
Serum
Cardiomyopathies
Cardiac Myocytes
Ionization
Albumins
Desorption
Carrier Proteins
Lasers

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Heart disease, clinical proteomics and mass spectrometry. / Stanley, Brian A.; Gundry, Rebekah L.; Cotter, Robert J.; Van Eyk, Jennifer E.

In: Disease Markers, Vol. 20, No. 3, 01.01.2004, p. 167-178.

Research output: Contribution to journalReview article

Stanley, BA, Gundry, RL, Cotter, RJ & Van Eyk, JE 2004, 'Heart disease, clinical proteomics and mass spectrometry', Disease Markers, vol. 20, no. 3, pp. 167-178. https://doi.org/10.1155/2004/965261
Stanley, Brian A. ; Gundry, Rebekah L. ; Cotter, Robert J. ; Van Eyk, Jennifer E. / Heart disease, clinical proteomics and mass spectrometry. In: Disease Markers. 2004 ; Vol. 20, No. 3. pp. 167-178.
@article{0467756a535e4da4a25ed49e54649c9f,
title = "Heart disease, clinical proteomics and mass spectrometry",
abstract = "Heart disease is the leading cause of mortality and morbidity in the world. As such, biomarkers are needed for the diagnosis, prognosis, therapeutic monitoring and risk stratification of acute injury (acute myocardial infarction (AMI)) and chronic disease (heart failure). The procedure for biomarker development involves the discovery, validation, and translation into clinical practice of a panel of candidate proteins to monitor risk of heart disease. Two types of biomarkers are possible; heart-specific and cardiovascular pulmonary system monitoring markers. Here we review the use of MS in the process of cardiac biomarker discovery and validation by proteomic analysis of cardiac myocytes/tissue or serum/plasma. An example of the use of MS in biomarker discovery is given in which the albumin binding protein sub-proteome was examined using MALDI-TOF MS/MS. Additionally, an example of MS in protein validation is given using affinity surface enhanced laser desorption ionization (SELDI) to monitor the disease-induced post-translational modification and the ternary status of myoctye-originating protein, cardiac troponin I in serum.",
author = "Stanley, {Brian A.} and Gundry, {Rebekah L.} and Cotter, {Robert J.} and {Van Eyk}, {Jennifer E.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1155/2004/965261",
language = "English (US)",
volume = "20",
pages = "167--178",
journal = "Disease Markers",
issn = "0278-0240",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - Heart disease, clinical proteomics and mass spectrometry

AU - Stanley, Brian A.

AU - Gundry, Rebekah L.

AU - Cotter, Robert J.

AU - Van Eyk, Jennifer E.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Heart disease is the leading cause of mortality and morbidity in the world. As such, biomarkers are needed for the diagnosis, prognosis, therapeutic monitoring and risk stratification of acute injury (acute myocardial infarction (AMI)) and chronic disease (heart failure). The procedure for biomarker development involves the discovery, validation, and translation into clinical practice of a panel of candidate proteins to monitor risk of heart disease. Two types of biomarkers are possible; heart-specific and cardiovascular pulmonary system monitoring markers. Here we review the use of MS in the process of cardiac biomarker discovery and validation by proteomic analysis of cardiac myocytes/tissue or serum/plasma. An example of the use of MS in biomarker discovery is given in which the albumin binding protein sub-proteome was examined using MALDI-TOF MS/MS. Additionally, an example of MS in protein validation is given using affinity surface enhanced laser desorption ionization (SELDI) to monitor the disease-induced post-translational modification and the ternary status of myoctye-originating protein, cardiac troponin I in serum.

AB - Heart disease is the leading cause of mortality and morbidity in the world. As such, biomarkers are needed for the diagnosis, prognosis, therapeutic monitoring and risk stratification of acute injury (acute myocardial infarction (AMI)) and chronic disease (heart failure). The procedure for biomarker development involves the discovery, validation, and translation into clinical practice of a panel of candidate proteins to monitor risk of heart disease. Two types of biomarkers are possible; heart-specific and cardiovascular pulmonary system monitoring markers. Here we review the use of MS in the process of cardiac biomarker discovery and validation by proteomic analysis of cardiac myocytes/tissue or serum/plasma. An example of the use of MS in biomarker discovery is given in which the albumin binding protein sub-proteome was examined using MALDI-TOF MS/MS. Additionally, an example of MS in protein validation is given using affinity surface enhanced laser desorption ionization (SELDI) to monitor the disease-induced post-translational modification and the ternary status of myoctye-originating protein, cardiac troponin I in serum.

UR - http://www.scopus.com/inward/record.url?scp=4744351348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4744351348&partnerID=8YFLogxK

U2 - 10.1155/2004/965261

DO - 10.1155/2004/965261

M3 - Review article

C2 - 15502250

AN - SCOPUS:4744351348

VL - 20

SP - 167

EP - 178

JO - Disease Markers

JF - Disease Markers

SN - 0278-0240

IS - 3

ER -